Time dependent dual effect of anti-inflammatory treatments on sarin-induced brain inflammation: Suggested role of prostaglandins

2019 ◽  
Vol 74 ◽  
pp. 19-27
Author(s):  
Shira Chapman ◽  
Ettie Grauer ◽  
Rellie Gez ◽  
Inbal Egoz ◽  
Shlomi Lazar
2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Sansan Hua ◽  
C. Joakim Ek ◽  
Carina Mallard ◽  
Maria E. Johansson

Inflammation plays a central role in neonatal brain injury. During brain inflammation the resident macrophages of the brain, the microglia cells, are rapidly activated. In the periphery,α7 nicotinic acetylcholine receptors (α7R) present on macrophages can regulate inflammation by suppressing cytokine release. In the current study we investigatedα7R expression in neonatal mice after hypoxia-ischemia (HI). We further examined possible anti-inflammatory role ofα7R stimulationin vitroand microglia polarization afterα7R agonist treatment. Real-time PCR analysis showed a 33% reduction inα7R expression 72 h after HI. Stimulation of primary microglial cells with LPS in combination with increasing doses of the selectiveα7R agonist AR-R 17779 significantly attenuated TNFαrelease and increasedα7R transcript in microglial cells. Gene expression of M1 markers CD86 and iNOS, as well as M2 marker CD206 was not influenced by LPS and/orα7R agonist treatment. Further, Mox markers heme oxygenase (Hmox1) and sulforedoxin-1 (Srx1) were significantly increased, suggesting a polarization towards the Mox phenotype afterα7R stimulation. Thus, our data suggest a role for theα7R also in the neonatal brain and support the anti-inflammatory role ofα7R in microglia, suggesting thatα7R stimulation could enhance the polarization towards a reparative Mox phenotype.


2008 ◽  
Vol 198 (1) ◽  
pp. 219-230 ◽  
Author(s):  
Silvia Tapia-Gonzalez ◽  
Paloma Carrero ◽  
Olga Pernia ◽  
Luis M Garcia-Segura ◽  
Yolanda Diz-Chaves

It has been previously reported that the neuroprotective hormone oestradiol reduces microglia inflammatory activity. The objective of this study was to test whether two selective oestrogen receptor modulators, tamoxifen and raloxifene, modulate in vivo the activation of microglia induced by the peripheral administration of lipopolysaccharide (LPS). Activation of microglia was assessed in the white matter of the cerebellum using immunoreactivity for major histocompatability complex-II. Oestradiol, tamoxifen and raloxifene decreased microglia activation induced by LPS in male and ovariectomized female rats, although the doses of oestradiol that were effective in decreasing microglia reactivity were not the same in both sexes. Tamoxifen reduced microglia activation in all experimental groups at all doses tested (0.5–2 mg/kg b.w.) while raloxifene lost its anti-inflammatory activity at the higher dose tested (2 mg/kg b.w). In addition, raloxifene had per se a moderate pro-inflammatory activity in the brain of control female rats and its anti-inflammatory activity was partially impaired in female animals after 1 month of deprivation of ovarian hormones. Spots of oestrogen receptor (ER)-α immunoreactivity were detected in the soma and cell processes of microglia. Treatment with LPS, oestradiol or tamoxifen induced an increase of ER-α immunoreactive spots in the perikaryon of microglia, while oestradiol antagonized the effect of LPS. The results indicate that some oestrogenic compounds decrease brain inflammation by a mechanism that may involve ERs expressed by microglia. The findings support the potential therapeutic role of oestrogenic compounds as protective anti-inflammatory agents for the central nervous system.


2019 ◽  
Vol 26 (5) ◽  
pp. 837-854 ◽  
Author(s):  
Effimia Zacharia ◽  
Nikolaos Papageorgiou ◽  
Adam Ioannou ◽  
Gerasimos Siasos ◽  
Spyridon Papaioannou ◽  
...  

During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF.


Sign in / Sign up

Export Citation Format

Share Document